Active, not recruitingPhase 1NCT04978727
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Clare Twist, MDRoswell Park Comprehensive Cancer Center
- Intervention
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years(biological)
- Enrollment
- 35 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2022 – 2030
Study locations (14)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Memorial Sloan Kettering, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
Roswell Park Cancer Institute · National Cancer Institute (NCI) · American Lebanese Syrian Associated Charities · Pediatric Brain Tumor Consortium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04978727 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah